- Conditions
- Moderate Alzheimer Disease
- Interventions
- SNK01, Placebo
- Biological · Other
- Lead sponsor
- NKGen Biotech, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Glendale, California • Santa Ana, California • Tarzana, California + 4 more
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 23, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Cognitive Decline, Dementia, Vascular, Alzheimer Disease, Dementia, Stroke
- Interventions
- Behavioral Dietary intervention ( MIND Diet), Behavioral Usual Care Diet Intervention
- Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Undiagnosed Disease, Healthy Volunteer (Adult With Typically Developing Child), Inherited Neurodegenerative Disorders, Inherited Metabolic Disorders (Inborn Errors of Metabolism), Alzheimer's Disease and Related Dementias
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 682 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Memphis, Tennessee
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
- Interventions
- repetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
- Device · Other
- Lead sponsor
- Chi-Ying (Roy) Lin
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease
- Interventions
- Citicoline supplement, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- ML-007C-MA, Placebo
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
- Conditions
- Alzheimer Disease
- Interventions
- ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
- Biological · Drug
- Lead sponsor
- Alzamend Neuro, Inc.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Doral, Florida
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
- Interventions
- IGC-AD1-Active, IGC-AD1-Placebo
- Drug
- Lead sponsor
- IGC Pharma, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more
- Conditions
- Alzheimer Disease
- Interventions
- Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Interventions
- DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
- Biological
- Lead sponsor
- Nuravax, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami Lakes, Florida
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Interventions
- Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
- Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
- Conditions
- Agitation Associated With Alzheimer's Dementia
- Interventions
- ITI-1284, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 31
- States / cities
- Anaheim, California • Costa Mesa, California • Garden Grove, California + 18 more
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.